Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women
2015년 2월 12일 업데이트: GlaxoSmithKline
A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655
This is a study to determine whether therapy with pazopanib is effective and safe in Asian women with epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has not progressed on first-line chemotherapy.
연구 개요
상세 설명
This study is an extension study to the VEG110655 study.
The parent study, VEG110655, was designed to evaluate whether pazopanib 800 mg daily for 52 weeks will prolong progression free survival (PFS) in women diagnosed with ovarian, fallopian tube or primary peritoneal cancer.
These women will have obtained stable disease, a complete remission, or a partial remission after debulking surgery and at least five cycles of chemotherapy (taxane/platinum).
This extension study will evaluate safety and efficacy outcomes of pazopanib monotherapy and placebo in an Asian population with the same indication as the parent study.
연구 유형
중재적
등록 (실제)
145
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Taipei, 대만, 104
- GSK Investigational Site
-
Taipei, 대만, 112
- GSK Investigational Site
-
-
-
-
-
Seoul, 대한민국, 135-710
- GSK Investigational Site
-
-
-
-
-
Beijing, 중국, 100044
- GSK Investigational Site
-
Beijing, 중국, 100021
- GSK Investigational Site
-
Beijing, 중국, 100853
- GSK Investigational Site
-
Shanghai, 중국, 200032
- GSK Investigational Site
-
-
Guangdong
-
Guangzhou, Guangdong, 중국
- GSK Investigational Site
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210009
- GSK Investigational Site
-
-
Liaoning
-
Shenyang, Liaoning, 중국, 110022
- GSK Investigational Site
-
-
Shandong
-
Jinan, Shandong, 중국, 250012
- GSK Investigational Site
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- GSK Investigational Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310006
- GSK Investigational Site
-
Hangzhou, Zhejiang, 중국, 310022
- GSK Investigational Site
-
-
-
-
-
Hong Kong, 홍콩
- GSK Investigational Site
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
여성
설명
Inclusion Criteria:
- written informed consent
- At least 18 years old.
- Histologically confirmed, International Federation of Gynecology and Obstetrics (FIGO) stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
- Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
- No evidence of disease progression
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2
- Able to swallow and retain oral medication.
- Adequate hematologic, hepatic, and renal system function as follows:
Hematologic
- Absolute neutrophil count (ANC) at least 1.5 X 10^9/L
- Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
- Platelets at least 100 X 10^9/L
- Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
- Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
- Total bilirubin up to 1.5 X ULN
- AST and ALT up to 2.5 X ULN Renal
- Serum creatinine up to 1.5 mg/dL
Or, if greater than 1.5 mg/dL:
Calculated creatinine clearance at least 50 mL/min Urine Protein
- Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or < 1.0 gram determined by 24-hour urine protein analysis.
- Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.
Exclusion Criteria:
- Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
- Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
- Clinically significant gastrointestinal abnormalities
- Prolongation of corrected QT interval (QTc) > 480 msecs
- History of any one or more cardiovascular conditions within the past 6 months prior to randomization
- Poorly controlled hypertension
- History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
- Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
- Evidence of active bleeding or bleeding diathesis.
- Hemoptysis within 6 weeks prior to randomization.
- Endobronchial metastases.
- Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
- Investigational or anti-VEGF anticancer therapy prior to study randomization.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib.
- Prior or concurrent invasive malignancies that currently or within the last 5 years show/ed activity of disease (except ovarian, fallopian tube, or peritoneal cancer, or concurrent endometrial cancer FIGO stages IA/B)
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약
위약 비교기
|
Placebo 800 mg daily for 24 months
|
|
실험적: pazopanib
experimental medication
|
Pazopanib 800 mg daily for 24 months
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free Survival (PFS)
기간: From randomization until evidence of progressive disease or death, whichever occurred first (average of 15.2 months)
|
PFS is defined as the time interval between randomization and evidence of progressive disease (PD), as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death, whichever occurred first.
A visit-based analysis approach to determine participants' dates of progression was applied in the analysis method.
PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Participants who were alive and had not progressed at the time of analysis were censored at the date associated with the last visit with adequate assessment.
|
From randomization until evidence of progressive disease or death, whichever occurred first (average of 15.2 months)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival
기간: From randomization until death due to any cause (average of 29.4 months)
|
Overall survival is defined as the time interval from the date of randomization to the date of death due to any cause.
|
From randomization until death due to any cause (average of 29.4 months)
|
|
PFS by Gynaecologic Cancer Intergroup (GCIG) Criteria
기간: From randomization to the earliest date of disease progression per GCIG criteria or death due to any cause (average of 15.2 months)
|
PFS by GCIG criteria is defined as the time from the randomization date to the earliest date of disease progression (PD) per GCIG criteria or death due to any cause.
Per GCIG criteria, an objective progression is defined as the earliest event of either tumor progression based on RECIST v1.0 or confirmed CA-125 progression.
A participant is counted as "Progressed per RECIST" if the radiological PD per RECIST occurred prior to or on the same day as CA-125 progression.
A participant is counted as "Progressed per CA-125" if the radiological PD occurred after CA-125 progression.
Per RECIST, PD is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Participants who were alive and had not progressed at the time of analysis were censored at the date associated with the last visit with adequate assessment.
|
From randomization to the earliest date of disease progression per GCIG criteria or death due to any cause (average of 15.2 months)
|
|
Number of Participants With Any Dose Reduction or Any Dose Interruption
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
Dose interruptions or reductions may have been required following potential drug-related toxicities.
As a general rule, if dose reduction of investigational product (IP) was necessary, the dose should have been reduced stepwise by 200 mg at each step, and the participant should have been monitored for 10 to 14 days.
If toxicity recurred or worsened during this monitoring time, the IP could have been interrupted and/or the dose of IP further decreased, with continued monitoring for an additional 10 to 14 days, and so on.
The cut off for these data was October 12, 2012.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious Adverse Event (SAE)
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalizaton or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.
See the non-serious AE/SAE module for a list of specific events.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With Any On-therapy AE and Any AE Related to Study Treatment
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
On-therapy AEs were those reported from the first day that randomized study drug was received to 28 days after the last dose of randomized study drug, and within 28 days of dose interruption.
Relatedness was assessed by the Investigator.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With Any Grade 3 or 4 AE
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
The NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0 was used to grade AEs per the following scale to assess severity: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling AE; Grade 5, death related to AE.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With the Indicated On-therapy Grade 3-5 AEs
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
On-therapy AEs were those reported from the first day that randomized study drug was received to 28 days after the last dose of randomized study drug, and within 28 days of dose interruption.
The NCI-CTCAE Version 3.0 was used to grade AEs per the following scale to assess severity: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening or disabling AE; Grade 5, death related to AE. ALT=alanine aminotransferase; AST=aspartate aminotransferase.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With AEs Leading to Permanent Discontinuation of Study Treatment, Dose Interruption, and Dose Reduction
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
Dose interruptions or reductions may have been required following potential drug-related toxicities.
As a general rule, if dose reduction of investigational product (IP) was necessary, the dose should have been reduced stepwise by 200 mg at each step, and the participant should have been monitored for 10 to 14 days.
If toxicity recurred or worsened during this monitoring time, the IP could have been interrupted and/or the dose of IP further decreased, with continued monitoring for an additional 10 to 14 days, and so on.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With Any SAE, Any SAE Related to Study Treatment, and Any Fatal SAE
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalizaton or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.
See the non-serious AE/SAE module for a list of specific events.
Relatedness was assessed by the Investigator.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With the Indicated Worst-case On-therapy Blood Pressure Shifts From Baseline
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
Systolic blood pressure (SBP) and Diatolic blood pressure (DBP) are measured in millimeters of mercury (mmHg).
A participant could have been counted in more than one shift category.
Participants who experienced shifts in both SBP and DBP are represented under each individual parameter.
A worst-case on-therapy shift is defined as the worst shift that occurred at any time during the treatment period.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With the Indicated Worst-case On-therapy Shift From Baseline in Bazett's Corrected QT Interval (QTc)
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
12-lead ECGs were obtained at the scheduled visits.
A worst-case on-therapy shift is defined as the worst shift that occurred at any time during the treatment period.
The QTc is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.
In general, the faster the heart rate the shorter the QTc.
If a QTc >=500 milliseconds (msec) was noted on a scheduled or unscheduled electrocardiogram (ECG), then two additional ECGs should have been obtained within 5 minutes to confirm the abnormality.
The average QTc was determined from the three ECG tracings by manual evaluation and was used to determine continued eligibility.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With the Indicated Worst-case On-therapy Hematology Parameter Grade Shifts From Baseline Grade
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
Grade shifts from Baseline were assessed as any grade increase (AGI), increase to Grade (G) 3 (ITG3), and increase to Grade 4 (ITG4).
Toxicities were graded according to the National Cancer Institute common toxicity criteria (NCI-Common Toxicity Criteria for Adverse Events), version 4.0.
Grade refers to the severity of the toxicity.
The CTCAE displays Grades (G) 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: G1, mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; G2, moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); G3, severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; G4, Life-threatening consequences; urgent intervention indicated.;
G5, death related to AE.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With the Indicated Worst-case On-therapy Chemistry Parameter Grade Shifts From Baseline Grade
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
Grade shifts from Baseline were assessed as any grade increase (AGI), increase to Grade (G) 3 (ITG3), and increase to Grade 4 (ITG4).
Toxicities were graded according to the National Cancer Institute common toxicity criteria (NCI-Common Toxicity Criteria for Adverse Events), version 4.0.
Grade refers to the severity of the toxicity.
The CTCAE displays Grades (G) 1 through 5 with unique clinical descriptions of severity for each toxicity based on the following general guideline: G1, mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; G2, moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); G3, severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; G4, Life-threatening consequences; urgent intervention indicated.;
G5, death related to AE.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
|
Number of Participants With the Indicated Worst-case Eastern Cooperative Oncology Group (ECOG) Performance Status Shifts From Baseline Grades of 0, 1, and 2
기간: From Week 1 until the end of the treatment period (up to Study Week 108)
|
The ECOG performance status scales and criteria are used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living abilities of the participant, and determine appropriate treatment and prognosis.
Grade 0, fully active, able to carry on all pre-disease performance without restriction.
Grade 1, restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
Grade 2, ambulatory and capable of all selfcare, but unable to carry out any work activities; up and about more than 50% of waking hours.
Grade 3, capable of only limited selfcare; confined to bed or chair more than 50% of waking hours.
Grade 4, completely disabled; cannot carry on any selfcare; totally confined to bed or chair.
Grade 5, dead.
|
From Week 1 until the end of the treatment period (up to Study Week 108)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2010년 9월 1일
기본 완료 (실제)
2012년 10월 1일
연구 완료 (실제)
2014년 1월 1일
연구 등록 날짜
최초 제출
2010년 10월 21일
QC 기준을 충족하는 최초 제출
2010년 10월 21일
처음 게시됨 (추정)
2010년 10월 25일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2015년 3월 3일
QC 기준을 충족하는 마지막 업데이트 제출
2015년 2월 12일
마지막으로 확인됨
2015년 2월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
신생물, 난소에 대한 임상 시험
-
Wolfson Medical Center빼는Ovarian Hyperstimulation Syndrome(OHSS)의 위험 감소를 위한 Coasting에 대한 GnRH 길항제의 증량 투여
Pazopanib에 대한 임상 시험
-
Imbioray (Hangzhou) Biomedicine Co., Ltd.아직 모집하지 않음
-
Institut Claudius RegaudNovartis종료됨
-
Centre Leon BerardNovartis; National Cancer Institute, France모집하지 않고 적극적으로
-
Centre Antoine LacassagneGlaxoSmithKline모집하지 않고 적극적으로
-
Shandong Cancer Hospital and Institute모병
-
Tianjin Medical University Second Hospital모병고형 종양, 성인 | 차세대 시퀀싱 | 정밀의학중국
-
Cure HHTUnited States Department of Defense; Food and Drug Administration (FDA)모집하지 않고 적극적으로
-
Pfizer완전한전이성 신장 세포 암종(mRCC)프랑스, 스페인, 이탈리아, 영국, 벨기에, 오스트리아, 그리스, 네덜란드